ライフサイエンスコーパス: antiarrhythmic agent

1 and these findings support its utility as an antiarrhythmic agent.

2 factors, when patients are treated with this antiarrhythmic agent.

3 of 40 derivatives of clofilium, a class III antiarrhythmic agent.

4 story of diabetes mellitus, and prior use of antiarrhythmic agents.

5 sis after excluding patients on pre-existing antiarrhythmic agents.

6 d susceptibility to proarrhythmic effects of antiarrhythmic agents.

7 jority of patients, necessitating the use of antiarrhythmic agents.

8 ate hERG currents and thus may act as potent antiarrhythmic agents.

9 c drug development from class I to class III antiarrhythmic agents.

10 ients) or therapy with class IC or class III antiarrhythmic agents (148 patients).

11 ee of atrial fibrillation without the use of antiarrhythmic agents; 84% were arrhythmia free when tho

12 In vitro and in vivo studies suggest that antiarrhythmic agents affect Na+ channels of cells from

13 ence of atrial arrhythmias without using any antiarrhythmic agents after the catheter ablation.

14 Because conventional antiarrhythmic agents aiming at ion channels have proven

15 ed to investigate the cellular uptake of the antiarrhythmic agent amiodarone, a phospholipidosis-indu

16 was reported in 1 of 1 RCT (100%) of class 1 antiarrhythmic agents and 5 of 5 RCTs (100%) of warfarin

17 drugs with narrow therapeutic indexes (e.g., antiarrhythmic agents, anticoagulant agents) have demons

18 Dronedarone is an antiarrhythmic agent approved in 2009 for the treatment

19 luate the potential role of ranolazine as an antiarrhythmic agent are warranted.

20 Although class III antiarrhythmic agents are being used increasingly for bo

21 brillation; the indications for conventional antiarrhythmic agents are decreasing because of side eff

22 lantable cardioverter defibrillators (ICDs), antiarrhythmic agents are increasingly being used as adj

23 Amiodarone is an antiarrhythmic agent commonly used in the treatment of s

24 Lidocaine is an antiarrhythmic agent commonly used to treat ventricular

25 incipal mechanisms of action of contemporary antiarrhythmic agents, delineates their limitations in t

26 Celivarone is a new antiarrhythmic agent developed for the treatment of vent

27 The antiarrhythmic agent disopyramide and various serotonin

28 heteroaromatic derivatives of the class III antiarrhythmic agent dofetilide was synthesized and asse

29 a(2+) release events and the response to the antiarrhythmic agent flecainide in Purkinje cells and ve

30 AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillati

31 Although there are established antiarrhythmic agents for preventing and treating postop

32 miodarone loading, and 3 required additional antiarrhythmic agents for sustained cardioversion.

33 of intravenous dofetilide, a pure class III antiarrhythmic agent, for the termination of sustained a

34 ollowed by the rapid, sequential infusion of antiarrhythmic agents (i.e., adenosine, verapamil, and e

35 The selective class III antiarrhythmic agent ibutilide prolongs action potential

36 We conclude that PUFAs may act as antiarrhythmic agents in vivo in normal and Ca2+-overloa

37 s, range: 1 to 241 days) failed at least two antiarrhythmic agents including either flecainide or sot

38 ompared with baseline (P:<0.001), but use of antiarrhythmic agents increased marginally (P:=0.05).

39 The Vaughn Williams classification divides antiarrhythmic agents into four groups according to thei

40 The development of selective atrial antiarrhythmic agents is a current strategy for suppress

41 Response to antiarrhythmic agents is mixed, and cardioversion is of

42 tter in humans by ibutilide, a new class III antiarrhythmic agent, is characterized by an increase in

43 Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardiov

44 isproportionate reporting similar to that of antiarrhythmic agents known to promote torsade de pointe

45 Our results show that the Class IB antiarrhythmic agent lidocaine blocks maintained inward

46 gest that sodium channel block with class IB antiarrhythmic agents may be effective in suppressing Td

47 ) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were tre

48 xamined the effect of ibutilide, a class III antiarrhythmic agent, on the energy requirement for atri

49 Rhythm control options are either antiarrhythmic agents or ablation, with each having its

50 concomitant, postcardioversion therapy with antiarrhythmic agents, patients will frequently have add

51 Dronedarone is a new antiarrhythmic agent pharmacologically related to amioda

52 The antiarrhythmic agent quinidine blocks the human cardiac

53 ocytes expressing Kv1.5-GFP with the class I antiarrhythmic agent quinidine resulted in a dose- and t

54 hythmic drug therapy; and (3) intolerance to antiarrhythmic agent requiring drug cessation.

55 The class III antiarrhythmic agent RP 58866 and its active enantiomer,

56 de fumarate is an intravenous (IV) class III antiarrhythmic agent that has been shown to be significa

57 ide fumarate is an investigational class III antiarrhythmic agent that prolongs repolarization by inc

58 Dronedarone is a new antiarrhythmic agent that was recently approved for the

59 ntial administration of different classes of antiarrhythmic agents until conversion to sinus rhythm w

60 neous influences of direct current shock and antiarrhythmic agents, which may independently depress l

61 hibit KvLQT1, whereas clofilium, a class III antiarrhythmic agent with the propensity to induce torsa

62 hus, there is a recognized need for improved antiarrhythmic agents with actions that are selective fo

63 a that it may be possible to develop class I antiarrhythmic agents with optimized pharmacodynamic pro